Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development

被引：23
|
作者：
Hargrove-Grimes, Passley [1 ]
Low, Lucie A. [1 ]
Tagle, Danilo A. [1 ]
机构：
[1] NIH, Natl Ctr Adv Translat Sci, Bldg 10, Bethesda, MD 20892 USA
来源：
CELLS TISSUES ORGANS | 2022年 / 211卷 / 03期
关键词：
Microphysiological systems; Microfluidics; Bioengineering; Induced pluripotent stem cells; Drug development; ON-A-CHIP; PLURIPOTENT STEM-CELLS; PHARMACEUTICAL-INDUSTRY; SAFETY ASSESSMENT; ORGANS; DEVICES; MODELS; ABSORPTION; INDUCTION; EFFICACY;
D O I：
10.1159/000517422
中图分类号：
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号：
100101 ;
摘要：
Microphysiological systems (MPS) or tissue chips/organs-on-chips are novel in vitro models that emulate human physiology at the most basic functional level. In this review, we discuss various hurdles to widespread adoption of MPS technology focusing on issues from multiple stakeholder sectors, e.g., academic MPS developers, commercial suppliers of platforms, the pharmaceutical and biotechnology industries, and regulatory organizations. Broad adoption of MPS technology has thus far been limited by a gap in translation between platform developers, end-users, regulatory agencies, and the pharmaceutical industry. In this brief review, we offer a perspective on the existing barriers and how end-users may help surmount these obstacles to achieve broader adoption of MPS technology.
引用
收藏
页码：269 / 281
页数：13
相关论文
共 50 条
  • [1] Multiorgan Microphysiological Systems for Drug Development: Strategies, Advances, and Challenges
    Wang, Ying I.
    Carmona, Carlos
    Hickman, James J.
    Shuler, Michael L.
    [J]. ADVANCED HEALTHCARE MATERIALS, 2018, 7 (02)
  • [2] Opportunities and challenges in the wider adoption of liver and interconnected microphysiological systems
    Hughes, David J.
    Kostrzewski, Tomasz
    Sceats, Emma L.
    [J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2017, 242 (16) : 1593 - 1604
  • [3] Human microphysiological systems for drug development
    Roth, Adrian
    [J]. SCIENCE, 2021, 373 (6561) : 1304 - 1306
  • [4] Microphysiological systems: What it takes for community adoption
    Hargrove-Grimes, Passley
    Low, Lucie A.
    Tagle, Danilo A.
    [J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2021, 246 (12) : 1435 - 1446
  • [5] Tackling the Challenges of Schizophrenia Drug Development: Stakeholder Perspectives
    Brady, Linda
    Gordon, Joshua
    Mates, Sharon
    Sand, Michael
    Brannan, Stephen
    Cannon, Tyrone
    [J]. NEUROPSYCHOPHARMACOLOGY, 2020, 45 (SUPPL 1) : 24 - 25
  • [6] Application of Immunocompetent Microphysiological Systems in Drug Development : Current Perspective and Recommendations
    Wang, Xiaoting
    Kopec, Anna K.
    Collinge, Mark
    David, Rhiannon
    Grant, Christian
    Hardwick, Rhiannon N.
    Navratil, Aaron
    Patel, Nirav
    Rowan, Wendy
    Marshall, Nikki B.
    [J]. ALTEX-ALTERNATIVES TO ANIMAL EXPERIMENTATION, 2023, 40 (02) : 314 - 336
  • [7] Microphysiological Blood-Brain Barrier Systems for Disease Modeling and Drug Development
    Mulay, Atharva R.
    Hwang, Jihyun
    Kim, Deok-Ho
    [J]. ADVANCED HEALTHCARE MATERIALS, 2024, 13 (21)
  • [8] Development of Microphysiological Systems (MPSs) Based on Microfluidic Technology for Drug Discovery in Japan
    Kimura, Hiroshi
    [J]. YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2023, 143 (01): : 39 - 44
  • [9] Microphysiological models of neurological disorders for drug development
    Offeddut, Giovanni S.
    Shin, Yoojin
    Kamm, Roger D.
    [J]. CURRENT OPINION IN BIOMEDICAL ENGINEERING, 2020, 13 : 119 - 126
  • [10] Microphysiological systems for solid tumor immunotherapy: opportunities and challenges
    Abizanda-Campo, Sara
    Virumbrales-Munoz, Maria
    Humayun, Mouhita
    Marmol, Ines
    Beebe, David J.
    Ochoa, Ignacio
    Olivan, Sara
    Ayuso, Jose M.
    [J]. MICROSYSTEMS & NANOENGINEERING, 2023, 9 (01)
12345